BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BioCentury | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new...
BioCentury | Apr 29, 2019
Clinical News

Patients highlight commonalities in rare diseases that could streamline drug development

Rare disease patients, advocates and caregivers who spoke at an FDA workshop on Monday highlighted multiple common symptoms across various diseases that could be used to streamline drug development. Attendees also cited the need for...
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
BioCentury | Feb 27, 2019
Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Oct 4, 2018
Translation in Brief

Risk Management Machinery

A Stanford University team has developed an AI platform that combines genomic and electronic health record data to help manage the risk of disease and identify new therapeutic targets. The group plans to out-license the...
Items per page:
1 - 10 of 157
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BioCentury | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new...
BioCentury | Apr 29, 2019
Clinical News

Patients highlight commonalities in rare diseases that could streamline drug development

Rare disease patients, advocates and caregivers who spoke at an FDA workshop on Monday highlighted multiple common symptoms across various diseases that could be used to streamline drug development. Attendees also cited the need for...
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
BioCentury | Feb 27, 2019
Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Oct 4, 2018
Translation in Brief

Risk Management Machinery

A Stanford University team has developed an AI platform that combines genomic and electronic health record data to help manage the risk of disease and identify new therapeutic targets. The group plans to out-license the...
Items per page:
1 - 10 of 157